Companies settle trade secret dispute over anaesthetic ingredient
Drugmaker Genus Lifesciences and pharmaceutical company Mallinckrodt have agreed to settle their trade secret dispute related to a cocaine hydrochloride formulation (HCI).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 September 2022 Suit claims a contractor used AltaThera secrets to launch a rival heart arrhythmia drug | Chicago-based company wants the court to add its founder as co-inventor on patent.
3 December 2019 Genus Lifesciences is suing pharmaceutical company Mallinckrodt for misusing trade secrets related to a cocaine hydrochloride formulation.